More Study Needed of Possible Carcinogenesis of Winter Gas Additive

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WASHINGTON--Although the chemical MTBE, added to gasoline in the winter to reduce the emission of carbon monoxide, does not pose a substantial human health risk, more study needs to be undertaken to assess both short- and long-term health effects, a National Research Council (NRC) committee said in its review of a draft of a federal report.

WASHINGTON--Although the chemical MTBE, added to gasoline in thewinter to reduce the emission of carbon monoxide, does not posea substantial human health risk, more study needs to be undertakento assess both short- and long-term health effects, a NationalResearch Council (NRC) committee said in its review of a draftof a federal report.

The federal study assessed the effects of methyl-tertiary-butylether (MTBE) on air and water quality, motor vehicles (fuel economyand engine performance), and public health.

In areas that have not met air quality standards for carbon monoxide,federal law requires the use of additives that increase oxygenlevels in gas during winter months when lower temperatures tendto cause vehicles to emit more carbon monoxide. However, availabledata indicate that oxygenated fuels reduce winter air levels ofcarbon monoxide by as little as 0% to about 10%, the committeesaid.

The NRC committee disagreed with the report's conclusion thatonly a small percentage of the population may be sensitive toMTBE, citing studies showing an increase in health problems amongworkers exposed to MTBE on the job.

In addition, the panel said, cancer estimates for MTBE were basedon animal models and should not be taken as conclusive. The committeerecommended that further investigations be made into MTBE as apotential carcinogen.

Recent Videos
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
1 expert is featured in this series.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Related Content